Oncolytics (ONC) Secures U.S. Patent, Extends Pelareorep Manufacturing Protection to 2044

Oncolytics Biotech (ONC) announced June 17, 2026, it has been granted a new U.S. patent (Patent No. 11,993,425) covering the manufacturing process for its lead asset, Pelareorep. This patent significantly extends the company's intellectual property protection for the oncolytic virus until at least 2044. The newly issued patent specifically covers methods of manufacturing Pelareorep, a proprietary immunotherapeutic virus. This extension provides Oncolytics with long-term intellectual property rights, bolstering the commercial potential and competitive positioning of Pelareorep as it progresses through clinical development and potential commercialization.